Acquired Company

Aurinia Pharmaceuticals (Aurinia Pharma U.S., Inc.) completed its acquisition of Kezar Life Sciences on May 11, 2026, pursuant to a tender offer and merger for $6.955 per share in cash plus one contingent value right (CVR).

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Show more

4000 Shoreline Court, South San Francisco, CA, 94080, United States

https://www.kezarlifesciences.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

53.86M

52 Wk Range

$3.53 - $7.55

Previous Close

$7.29

Open

$7.29

Volume

N/A

Day Range

$7.29 - $7.29

Enterprise Value

-15.62M

Cash

71.88M

Avg Qtr Burn

-11.96M

Insider Ownership

15.78%

Institutional Own.

61.26%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zetomipzomib (KZR-616) Details Autoimmune Hepatitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KZR-261 Details Solid tumor/s, Melanoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zetomipzomib (KZR-616) Details Chronic inflammatory disorder, Chronic kidney disease, Inflammatory disease, Kidney disease, Lupus nephritis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KZR-616 Details Chronic inflammatory disorder, Inflammatory disease, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.